Abstract
Methotrexate (MTX) has been used in combination with nonsteroidal anti-inflammatory drugs in the treatment of inflammatory diseases as well as malignancies. Severe adverse effects with this combination may occur, usually resulting from inhibition of renal transporters. Solid Ehrlich Carcinoma was experimentally induced by implantation of Ehrlich Ascites Carcinoma cells subcutaneously into the thigh of mice, and after 30 days, mice were divided into three groups: Group I that served as control group received MTX (50 mg/kg, i.p.); Group II received ketoprofen (100 mg/kg, i.p.) and then after half an hour received MTX (50 mg/kg, i.p.); Group III received indomethacin (10 mg/kg, i.p.) and then after half an hour received MTX (50 mg/kg, i.p.). Plasma and tissue samples were collected at different time points and then MTX concentrations were determined by HPLC. The injection of ketoprofen or indomethacin before MTX injection resulted in significant increase in the AUC and CPmax of MTX (p < 0.05) and significant decrease in CL/F and Vd/F of MTX (p < 0.05) in mice plasma. The effects were more significant after injection of indomethacin than in case of ketoprofen. The study showed that administration of ketoprofen or indomethacin prior to MTX caused significant decrease in MTX elimination and significant increase in MTX extent of absorption which may lead to severe adverse effects if coadministered in human.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brouwers J, de Smet P (1994) Pharmacokinetic—pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 27:462–485
Cedron LA, Sayalero ML, Lanao JM (1999) High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. Chromatogr B Biomed Sci Appl 721(2):271–280
Cowan DS, Tannock IF (2001) Factors that Iinfluence the penetration of methotrexate through solid tissue. Int J Cancer 91:120–125
El-Sheikh AA, Van den Heuvel JJ, Koenderink JB et al (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. JPET 320(1):229–235
Guo P, Wang X, Liu L et al (2007) Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 43:1789–1795
Iqbal MP, Baiga JA, Ali AA et al (1998) The Effects of non-steroidal anti-inflammatory drugs on the fisposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos 19:163–170
Lee C, Macgregor P (2004) Using microarrays to predict resistance to chemotherapy in cancer patients. Pharmacogenomics 5(6):611–625
Löscher W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76(1):22–76
Maeda A, Tsuruoka S, Kanai Y et al (2008) Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol 596(1–3):166–172
Majumdar S, Aggarwal BB (2001) Methotrexate suppresses NF-kappaB activation through inhibition of IkappaB alpha phosphorylation and degradation. J Immunol 167(5):2911–2920
Najjar TA (1995) Effect of cefoperazone on the pharmacokinetics of methotrexate in the rabbit. Int J Pharm 131:67–71
Nozaki Y, Kusuhara H, Endou H et al (2004) Quantitative evaluation of the drug–drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 309:226–234
Rubino FM (2001) Separation methods for methotrexate, its structural analogues and metabolites. J Chromatogr B Biomed Sci Appl 764(1–2):217–254
Shibayama Y, Ushinohama K, Ikeda R et al (2006) Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci 97:1260–1266
Stewart CF, Fleming RA, Germain BF et al (1991) Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 34:1514–1520
Takeda M, Khamdang S, Narikawa S et al (2002) Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302(2):666–671
Tracy TS, Worster T, Bradley JD et al (1994) Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 37(5):453–460
Trédan O, Galmarini CM, Patel K et al (2007) Drug Resistance and the Solid Tumor Microenvironment. J Natl Cancer Inst 99:1441–1454
Zhou SF, Wang LL, Di YM et al (2008) Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15(20):1981–2039
Acknowledgments
All authors gave substantial contributions to the conception and design of study, analysis and interpretation of the data, drafting and revising the article.
Conflict of Interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elmorsi, Y.M., El-Haggar, S.M., Ibrahim, O.M. et al. Effect of ketoprofen and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues. Eur J Drug Metab Pharmacokinet 38, 27–32 (2013). https://doi.org/10.1007/s13318-012-0113-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-012-0113-x